308 related articles for article (PubMed ID: 32114397)
1. Pathways towards human immunodeficiency virus elimination.
Dash PK; Kevadiya BD; Su H; Banoub MG; Gendelman HE
EBioMedicine; 2020 Mar; 53():102667. PubMed ID: 32114397
[TBL] [Abstract][Full Text] [Related]
2. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
3. Long-acting slow effective release antiretroviral therapy.
Edagwa B; McMillan J; Sillman B; Gendelman HE
Expert Opin Drug Deliv; 2017 Nov; 14(11):1281-1291. PubMed ID: 28128004
[TBL] [Abstract][Full Text] [Related]
4. Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice.
Dash PK; Kaminski R; Bella R; Su H; Mathews S; Ahooyi TM; Chen C; Mancuso P; Sariyer R; Ferrante P; Donadoni M; Robinson JA; Sillman B; Lin Z; Hilaire JR; Banoub M; Elango M; Gautam N; Mosley RL; Poluektova LY; McMillan J; Bade AN; Gorantla S; Sariyer IK; Burdo TH; Young WB; Amini S; Gordon J; Jacobson JM; Edagwa B; Khalili K; Gendelman HE
Nat Commun; 2019 Jul; 10(1):2753. PubMed ID: 31266936
[TBL] [Abstract][Full Text] [Related]
5. TLR1/2 Agonist Enhances Reversal of HIV-1 Latency and Promotes NK Cell-Induced Suppression of HIV-1-Infected Autologous CD4
Duan S; Xu X; Wang J; Huang L; Peng J; Yu T; Zhou Y; Cheng K; Liu S
J Virol; 2021 Aug; 95(17):e0081621. PubMed ID: 34133900
[TBL] [Abstract][Full Text] [Related]
6. Activation of Latent HIV-1 T Cell Reservoirs with a Combination of Innate Immune and Epigenetic Regulators.
Palermo E; Acchioni C; Di Carlo D; Zevini A; Muscolini M; Ferrari M; Castiello L; Virtuoso S; Borsetti A; Antonelli G; Turriziani O; Sgarbanti M; Hiscott J
J Virol; 2019 Nov; 93(21):. PubMed ID: 31413127
[TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
[TBL] [Abstract][Full Text] [Related]
8. Eradicating HIV-1 infection: seeking to clear a persistent pathogen.
Archin NM; Sung JM; Garrido C; Soriano-Sarabia N; Margolis DM
Nat Rev Microbiol; 2014 Nov; 12(11):750-64. PubMed ID: 25402363
[TBL] [Abstract][Full Text] [Related]
9. A Review of Current Strategies Towards the Elimination of Latent HIV-1 and Subsequent HIV-1 Cure.
Maina EK; Adan AA; Mureithi H; Muriuki J; Lwembe RM
Curr HIV Res; 2021; 19(1):14-26. PubMed ID: 32819259
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 cure strategies: why CRISPR?
Atkins AJ; Allen AG; Dampier W; Haddad EK; Nonnemacher MR; Wigdahl B
Expert Opin Biol Ther; 2021 Jun; 21(6):781-793. PubMed ID: 33331178
[TBL] [Abstract][Full Text] [Related]
11. CRISPR editing of CCR5 and HIV-1 facilitates viral elimination in antiretroviral drug-suppressed virus-infected humanized mice.
Dash PK; Chen C; Kaminski R; Su H; Mancuso P; Sillman B; Zhang C; Liao S; Sravanam S; Liu H; Waight E; Guo L; Mathews S; Sariyer R; Mosley RL; Poluektova LY; Caocci M; Amini S; Gorantla S; Burdo TH; Edagwa B; Gendelman HE; Khalili K
Proc Natl Acad Sci U S A; 2023 May; 120(19):e2217887120. PubMed ID: 37126704
[TBL] [Abstract][Full Text] [Related]
12. HIV Proviral Burden, Genetic Diversity, and Dynamics in Viremic Controllers Who Subsequently Initiated Suppressive Antiretroviral Therapy.
Omondi FH; Sudderuddin H; Shahid A; Kinloch NN; Jones BR; Miller RL; Tsai O; MacMillan D; Trocha A; Brockman MA; Brumme CJ; Joy JB; Liang R; Walker BD; Brumme ZL
mBio; 2021 Dec; 12(6):e0249021. PubMed ID: 34781741
[TBL] [Abstract][Full Text] [Related]
13. Current and Future Therapeutic Strategies for Lentiviral Eradication from Macrophage Reservoirs.
Peterson TA; MacLean AG
J Neuroimmune Pharmacol; 2019 Mar; 14(1):68-93. PubMed ID: 30317409
[TBL] [Abstract][Full Text] [Related]
14. [Evolution and Diversity of HIV-1].
Metzner KJ
Praxis (Bern 1994); 2011 Jan; 100(1):29-35. PubMed ID: 21210358
[TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas9: a tool to eradicate HIV-1.
Bhowmik R; Chaubey B
AIDS Res Ther; 2022 Dec; 19(1):58. PubMed ID: 36457057
[TBL] [Abstract][Full Text] [Related]
16. CRISPR-Cas9 Mediated Exonic Disruption for HIV-1 Elimination.
Herskovitz J; Hasan M; Patel M; Blomberg WR; Cohen JD; Machhi J; Shahjin F; Mosley RL; McMillan J; Kevadiya BD; Gendelman HE
EBioMedicine; 2021 Nov; 73():103678. PubMed ID: 34774454
[TBL] [Abstract][Full Text] [Related]
17. Lentiviral Infections Persist in Brain despite Effective Antiretroviral Therapy and Neuroimmune Activation.
Mohammadzadeh N; Roda W; Branton WG; Clain J; Rabezanahary H; Zghidi-Abouzid O; Gelman BB; Angel JB; Cohen EA; Gill MJ; Li M; Estaquier J; Power C
mBio; 2021 Dec; 12(6):e0278421. PubMed ID: 34903055
[TBL] [Abstract][Full Text] [Related]
18. Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation.
Li P; Kaiser P; Lampiris HW; Kim P; Yukl SA; Havlir DV; Greene WC; Wong JK
Nat Med; 2016 Jul; 22(7):807-11. PubMed ID: 27294875
[TBL] [Abstract][Full Text] [Related]
19. Strategies to eradicate HIV from infected patients: elimination of latent provirus reservoirs.
Sadowski I; Hashemi FB
Cell Mol Life Sci; 2019 Sep; 76(18):3583-3600. PubMed ID: 31129856
[TBL] [Abstract][Full Text] [Related]
20. Modeling the Effects of Latency Reversing Drugs During HIV-1 and SIV Brain Infection with Implications for the "Shock and Kill" Strategy.
Roda WC; Liu S; Power C; Li MY
Bull Math Biol; 2021 Mar; 83(4):39. PubMed ID: 33712983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
